p-Tau217 blood tests for Alzheimer's are now available in Europe, but "approved" is not quite the right word. Two automated tests earned a CE Mark in 2026 — Roche's Elecsys pTau217 on 12 May and Beckman Coulter's Access p-Tau217 on 7 July — a European conformity marking, not a central approval from a single agency.
p-Tau217 (phosphorylated tau at threonine 217) is a protein measured in blood that rises when amyloid plaques build up in the brain, a hallmark of Alzheimer's disease. These tests help doctors evaluate people who already show signs of memory or thinking problems. They are an aid to diagnosis — not a standalone answer and not a screening tool for healthy people.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Roche official CE Mark announcement, Elecsys pTau217 — Use this primary source to verify the official announcement.
- Read the original research from NIH — Use this page to review the original research.
Table of Contents
- What "CE-marked" actually means here
- What the test measures — and what it does not
- Who these tests are for
- How Europe compares to the United States
- How accurate is it, and what happens to unclear results
- Frequently Asked Questions
What "CE-marked" actually means here
A CE Mark shows a product meets European Union safety and performance rules under the In Vitro Diagnostic Regulation (IVDR). It is a conformity marking, not a stamp of endorsement from a central body like the European Medicines Agency. That distinction matters when a headline says "approved." Roche announced its CE Mark for the Elecsys pTau217 test on 12 May 2026, developed with Eli Lilly to detect amyloid pathology.
Beckman Coulter followed with a CE Mark for its Access p-Tau217 assay on 7 July 2026, which runs on the DxI 9000 analyzer. Because more than one company is CE-marked, there is no single "approval event." Availability also depends on whether individual hospitals and labs adopt the specific analyzers these tests require. So "now available in Europe" is broadly true, but it is a gradual rollout, not a switch flipped everywhere at once.
What the test measures — and what it does not
The test measures amyloid pathology, the plaque buildup linked to Alzheimer's. Roche describes plasma p-Tau217 as a biomarker whose levels correlate with brain amyloid plaques. A raised result signals that this process is likely underway. Here is the key limit.
A positive test points to amyloid in the brain, but it does not by itself confirm Alzheimer's dementia or measure how severe someone's symptoms are. Amyloid can be present in people whose thinking is still intact, and other conditions cause cognitive decline too. That is why doctors read the result alongside a full clinical assessment — history, cognitive testing, and sometimes brain imaging. The blood test narrows the question; it does not close it.
Who these tests are for
These tests target adults already being evaluated for cognitive decline, not the general public. Beckman Coulter's assay is intended to support evaluation of amyloid pathology in patients with cognitive-decline symptoms. The U.S.
version applies specifically to symptomatic patients aged 55 and older. A quick check on who fits this use: If none of these apply, the test is not designed for your situation. Asymptomatic screening of the general population is not what these approvals cover.
- You or a relative already have memory or thinking symptoms under medical review
- A clinician is actively working through possible causes, including Alzheimer's
- The goal is to support a diagnosis, not to screen someone with no symptoms
How Europe compares to the United States
The European CE Mark is not the same as an FDA approval, and the timelines differ. The U.S. moved first: the FDA cleared Fujirebio's Lumipulse pTau217/β-Amyloid plasma ratio on 16 May 2025. Even that U.S.
milestone deserves a precise word. It was a 510(k) clearance based on substantial equivalence, not a full premarket "approval," and it applies to symptomatic patients aged 55 and up. So on both continents, the marketing language runs ahead of the regulatory reality. The practical takeaway: these are legitimate, regulator-recognized tests on both sides of the Atlantic. But "approved," "cleared," and "CE-marked" mean different things, and none of them means "definitive diagnosis in a single blood draw.".
How accurate is it, and what happens to unclear results
Accuracy is strong but not perfect. In Lumipulse validation, plasma results showed 91.7% positive and 97.3% negative concordance with amyloid PET scans or spinal-fluid testing. In plain terms, the test usually agrees with the more established methods.
The catch is the middle ground. Roughly 20% of results in that study fell into an indeterminate zone — neither clearly positive nor clearly negative — and needed confirmatory testing such as a PET scan or spinal fluid analysis. If your result lands there, expect a follow-up test rather than a final answer. For anyone weighing this test, that is the realistic expectation: a strong clue in most cases, a prompt for more testing in a meaningful minority, and always a result that a clinician interprets rather than the number speaking for itself.
Frequently Asked Questions
Can I ask my doctor for this test if I have no symptoms?
No. These tests are meant for people already being evaluated for cognitive decline, not for screening healthy adults without symptoms.
Does a positive result mean I have Alzheimer's?
Not on its own. It indicates amyloid pathology in the brain, which a doctor must interpret alongside cognitive testing and clinical assessment.
Is a CE Mark the same as EMA or FDA approval?
No. A CE Mark is a European conformity marking under the IVDR. It differs from an FDA 510(k) clearance and is not a central EMA approval.
